Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica’s cold treatment product, ColdZyme Mouth Spray, on the Nordic market.

Under the agreement, the product will be on sale in around 3,200 pharmacies and a large number of stores, including health food retailers, in the Nordic region. Actavis ColdZyme Mouth spray will be licensed for distribution and sale in Sweden, Denmark, Finland, Norway and Iceland. Actavis anticipates launching ColdZyme for sale in Sweden during the second half of 2013, and in the other Nordic countries during 2014. The deal between Enzymatica and Actavis is expected to be finalised by the end of June this year at the latest. According to a press release by Enzymatica, it is estimated that the ColdZyme Mouth Spray will achieve net sales totalling SEK 350-400 million in the Nordic retail sector over the next five years.

ColdZyme Mouth spray was registered with the Swedish Medical Products Agency as a class 1 medical product in August 2012.  During the first quarter of 2013, ColdZyme went on sale at the outlets of the Kronans Droghandel and Apotek Hjärtat chains of pharmacies in Sweden, alongside earlier sales in health stores.

Enzymatica, which is currently listed on the Aktietorget stock exchange, announced in April hat the company is planning to change lists and has decided to begin the rocess of listing on NASDAQ OMX tockholm Stock Exchange during the first six months of 2014.